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Abstract. Vascular endothelial growth factor (VEGF) is
produced by most tumour types and stimulates the growth of
new blood vessels in the tumour. The expansion of a solid
tumour ultimately leads to the development of hypoxic regions,
which increases VEGF production and further angiogenesis.
In this study, we examined the role of VEGF in the survival
of breast tumour cells under hypoxia. Murine 4T1 and human
MDA-MB-231 tumour cells were cultured under normoxic
and hypoxic growth conditions in the presence or absence of
VEGF neutralising antibodies. Apoptosis was assessed in
addition to changes in expression of the anti- and pro-apoptotic
proteins, Bcl-2 and Bad, respectively. The effect of hypoxia
on the novel VEGF receptor, NP1 (neuropilin-1) and the role
of the PI3K (phosphatidylinositol-3-kinase) signalling pathway
in response to VEGF were examined. VEGF blockade resulted
in direct tumour cell apoptosis of both tumour cell lines under
normoxia and hypoxia. While blocking VEGF resulted in a
downregulation of hypoxia-induced Bcl-2 expression, there
was a significant increase in the pro-apoptotic protein Bad
relative to cells cultured under hypoxia alone. Both hypoxia
and VEGF phosphorylated Akt. Neutralising antibodies to
VEGF abrogated this effect, implicating the PI3K pathway in
VEGF-mediated cell survival of mammary adenocarcinoma
cells. This study demonstrates that VEGF acts as a survival
factor not only for endothelial cells as previously thought,
but also for some breast tumour cells, protecting them from
apoptosis, particularly under hypoxic stress. The data presented
provide an additional rationale for combining anti-VEGF
strategies with conventional anti-cancer therapies such as
chemotherapy and radiotherapy.
Introduction
As a solid tumour grows, its vascular supply becomes
inadequate resulting in a reduction in tissue oxygen tension.
Tumour hypoxia has been directly measured in a variety of
human cancers. In studies of head and neck carcinomas, it
was shown that hypoxia correlated with a lower probability
of disease-free survival (1,2). A significant correlation between
tumour metastasis and hypoxia was also demonstrated in
clinical studies of soft tissue sarcomas (3) and cervical
carcinoma (4). These findings suggest that hypoxia results in
more aggressive tumour behaviour in a number of tumour types
by altering fundamental, physiological important pathways.
In addition, hypoxia is a therapeutic obstacle as it renders
tumours resistant to conventional anti-cancer therapies such
and chemotherapy and radiotherapy (5-7). Elevated tumour
interstitial fluid pressure has also been shown to be responsible,
at least in part, for the poor penetration and heterogenous
distribution of therapeutic agents and nutrients to solid
tumours (8).
Angiogenesis, the growth of new vessels from the pre-
existing vasculature, is thought to be driven largely by tumour
hypoxia. Furthermore, the spread of malignant tumour cells
from the primary neoplasm to distant sites is influenced by
the angiogenic potential and oxygenation status of the tumour
(9,10). Tumour cells exposed to hypoxia show increased
expression of the pro-angiogenic protein, VEGF (vascular
endothelial growth factor) (11). Transient hypoxia promotes
the development of metastases in melanomas expressing low
VEGF levels by upregulating the expression of VEGF, thereby
enhancing the angiogenic potential of tumour cells (12). 
Inhibition of tumour growth in several tumour types using
blocking antibodies against VEGF has been documented
(13-15). Increases in the apoptotic fraction of tumour cells
and a reduction in vascular density and permeability have been
shown to result from neutralisation of VEGF or suppression
of VEGF expression (16). Emerging evidence indicates that,
in addition to its role as an endothelial cell mitogen, VEGF
also protects tumour cells from apoptosis (17-19). Although
there have been a number of studies highlighting the role of
VEGF as a survival factor for endothelial cells through a
number of mechanisms such as the induction of Bcl-2 (20),
interactions with integrins (21) and sustained angiogenesis
(22), the exact mechanisms of VEGF signalling in tumour
cells remain unclear. 
Materials and methods
Cell lines. The murine mammary adenocarcinoma 4T1 cell line
was generously provided by Dr Fred Miller (Duke University,
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NC, USA). The MDA-MB-231 human mammary adeno-
carcinoma cell line was purchased from the American Tissue
Culture Collection (ATCC). 4T1 tumour cells were maintained
in Roswell Park Memorial Institute medium (RPMI-1640)
in a humidified atmosphere of 5% CO2 in air at 37˚C. MDA-
MB-231 cells were maintained in sealed flasks with Leibovitz
(L-15) culture medium at 37˚C. All media were supplemented
with 10% heat-inactivated fetal bovine serum (FBS), penicillin
(100 U/ml) and streptomycin (100 μg/ml) (Gibco BRL,
UK). All cells were maintained as monolayer cultures and
exponentially growing cultures were used for experiments.
TUNEL assay. Apoptosis was assessed using the in situ cell
death detection kit (Roche Diagnostics, Germany). 4T1 and
MDA-MB-231 tumour cells were seeded on plastic (Gibco
BRL) or glass (Becton Dickinson, CA, USA) chamber slides,
respectively, at a concentration of 5x104 cells/chamber in
triplicate, for each condition. Cells were allowed to recover
overnight and then treated for 24 h under normoxia (21% O2)
or hypoxia (2% O2) in the presence or absence of VEGF
neutralising antibodies (1 μg/ml), with FBS in the culture
media reduced to 1% to increase baseline levels of apoptosis in
4T1 and MDA-MB-231 tumour cells. Cells were fixed in 100%
(v/v) methanol and stained according to the manufacturer's
instructions. Apoptotic cells were counted in five fields and
scored per sample (n=3).
VEGF ELISA. 4T1 and MDA-MB-231 cells were cultured
under normoxia (21% O2) or hypoxia (2% O2) for 24 h. Cell
culture supernatants were collected and any debris was pelleted
by centrifugation at 300 x g for 5 min. Cells were washed three
times in PBS, lysed and total protein measured using the
bicinchoninic acid (BCA) assay. VEGF production by 4T1
and MDA-MB-231 cells was measured using the Quantikine
murine or human VEGF ELISA kits (R&D Systems Europe,
Abingdon, UK), respectively. Results were expressed as pg
VEGF/μg of total cell protein.
Western immunoblotting. Cells were washed three times in
PBS and lysed for 1 h on ice in 1 ml of lysis buffer [5 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% (v/v)
Triton X-100, 0.5% (w/v) SDS, 0.5% (w/v) deoxycholic acid,
1 mM (w/v) phenylmethylsulphonyl fluoride]. For experiments
examining phosphorylated Akt, 1 mM sodium orthovanadate
was added to the lysis buffer. Total protein concentration was
determined using the BCA assay according to the manu-
facturer's instructions (Pierce, IL, USA). Proteins (50 μg)
were size-fractionated by 12% (Bcl-2, Bad and NP1) or
8% (phosphorlyated Akt) SDS-PAGE and transferred to
nitrocellulose membranes (PALL Corporation, FL, USA).
Membranes were incubated in blocking buffer [5% non-fat
dry milk in Tris-buffered saline (25 mM Tris-HCl, pH 7.6,
150 mM NaCl) containing 0.1% (v/v) Tween-20 (TBST)] for
1 h at room temperature and incubated for 60 min with the
appropriate primary antibody that was both murine and human
reactive. Blots were probed using anti-NP1 antibody (Santa
Cruz Biotech, CA, USA) diluted 1:100, anti-Bad antibody
(BD Pharmingen, UK) diluted 1:500, anti-Bcl-2 (Santa Cruz
Biotech, CA, USA) diluted 1:200 and anti-phospho Akt (Cell
Signalling, MA, USA) diluted 1:1000. All incubations of
primary antibodies were carried out in 5% blocking buffer.
Following six 5-min washes in TBST, membranes were
incubated for 90 min with the appropriate horseradish
peroxidase-conjugated secondary antibody (Dako, Glostrup,
Denmark), diluted 1:2000 in TBST. Bound antibody was
detected using enhanced chemiluminescence (ECL) (Pierce).
NP1, Bad and Bcl-2 blots were stripped and equal loading
was confirmed using a ß-actin antibody (Merck Biosciences,
UK) diluted 1:20,000 in 5% blocking buffer. Phospho-Akt
blots were also stripped and re-probed using antibody to total
Akt (BD Pharmingen), diluted 1:200 in 5% blocking buffer. 
Statistical analysis. Statistical comparison between groups was
carried out using analysis of variance (ANOVA) with Scheffe
post-hoc correction to examine any overall differences between
groups. Where the means of two data sets were compared,
an unpaired Student's t-test was used. Data is graphically
represented as mean ± SEM. All data was analysed using the
SPSS™ (SPSS Inc., IL, USA) statistical software package.
Results
Hypoxia increased VEGF production and Neuropilin-1
expression. 4T1 and MDA-MB-231 mammary adenocarcinoma
cells were cultured under normoxic or hypoxic growth
conditions for 24 h. Hypoxia significantly increased VEGF
production by 4T1 (36.30±2.92 pg VEGF/μg protein, Fig. 1A)
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Figure 1. Hypoxia induced VEGF production by breast tumour cells. 4T1 (A)
and MDA-MB-231 (B) tumour cells were cultured under normoxia (21% O2)
or hypoxia (2% O2) for 24 h. Cell culture supernatants were collected and
VEGF protein was measured by ELISA. Total cell protein was quantified by
BCA assay and VEGF expressed as pg/μg cell protein. Data are expressed
as the mean ± SEM. Statistical analysis was carried out by unpaired Student's
t-test (*p<0.05, hypoxia vs normoxia, n=3).
41-48  10/12/07  15:01  Page 42
and MDA-MB-231 (12.18±0.265 pg VEGF/μg protein,
Fig. 1B) cells relative to normoxia (4T1, 14.6±0.318 pg
VEGF/μg protein; MDA-MB-231, 7.35±0.45 pg VEGF/μg
protein; p<0.05). We have previously demonstrated that
hypoxia-induced VEGF can be prevented by anti-VEGF
antibodies. More recently, we have shown that 4T1 and MDA-
MB-231 cells express NP1 but not KDR/Flk-1 (VEGFR2)
(23). In addition to increasing VEGF production, hypoxia also
increased expression of NP1 in both 4T1 (Fig. 2A) and MDA-
MB-231 (Fig. 2B) cells. Densitometric analysis confirmed a
significant increase in NP1 expression under hypoxia in both
tumour cell lines (4T1, 319±31.32%, Fig. 2C; MDA-MB-231,
180±17.96%, Fig. 2D).
VEGF blockade induced breast tumour cell apoptosis. To
examine whether VEGF protects tumour cells from apoptosis
under hypoxic conditions, cells were cultured in chamber
slides and treated for 24 h with anti-VEGF antibodies under
normoxia (21% O2) or hypoxia (2% O2). Apoptosis was
determined using the TUNEL assay. Serum levels were
reduced from 10% to 1% to increase the basal levels of
apoptosis. Relative to normoxic controls, hypoxia had little
effect on tumour cell apoptosis. Treatment of cells under
normoxic conditions with anti-VEGF antibodies resulted in a
significant increase in apoptosis in both cell lines relative to
controls (4T1, 9.0±0.54% vs 5.3±0.78%, Fig. 3A; MDA-
MB-231, 8.42±1.26% vs 4.28±0.32%, Fig. 3B). Inclusion of
VEGF neutralising antibodies under hypoxia also resulted in
a significant induction of apoptosis in both cell lines, and to a
greater extent under hypoxia than normoxia (4T1, 12.36±1.39%
vs 9.0±0.54%; MDA-MB-231, 15.11±1.47% vs 8.42±1.26%).
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Figure 2. Neuropilin-1 (NP1) receptor protein is expressed on 4T1 (A) and
MDA-MB-231 (B) tumour cells. Cells were cultured under normoxia (21%
O2) or hypoxia (2% O2) for 24 h and NP1 receptor expression was examined
in both cell lines by Western blotting. Blots were stripped and re-probed
for ß-actin in both cell lines to control for equal loading. Blots shown are
representative of three independent experiments. Densitometric analysis
of NP1 expression in 4T1 (C) and MDA-MB-231 (D) tumour cells. NP1
expression was normalised to ß-actin and expressed as a percentage of
normoxic controls which were taken as 100%. Data are expressed as the
mean ± SEM. Statistical analysis was performed using an unpaired Student's
t-test (*p<0.01, hypoxia vs normoxia, n=3).
Figure 3. VEGF blockade induced tumour cell apoptosis. 4T1 (A) and
MDA-MB-231 (B) cells were cultured in chamber slides for 24 h under
normoxia (21% O2) or hypoxia (2% O2) in the presence or absence of VEGF
neutralising antibodies (1 μg/ml). Cells were stained using TUNEL and
apoptotic tumour cells were counted in five high-power fields per sample
(x400 magnification). Data expressed as mean ± SEM. Statistical analysis was
carried out by ANOVA with Scheffe post-hoc correction (*p<0.05, normoxia
+ VEGF Ab vs normoxia; $p<0.01, hypoxia + VEGF Ab vs hypoxia; #p<0.05
hypoxia + VEGF Ab vs normoxia + VEGF Ab, n=3).
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Representative TUNEL staining of 4T1 (Fig. 4A) and MDA-
MB-231 cells (Fig. 4B) are shown. Increased numbers of
TUNEL-positive (brown) cells with apoptotic morphology
were clearly visible in cells treated with anti-VEGF antibodies
under both normoxia and hypoxia. Blocking either baseline
VEGF (normoxia + VEGF Ab) or hypoxia-induced VEGF
(hypoxia + VEGF Ab) increased tumour cell apoptosis,
demonstrating a role for VEGF as a tumour cell survival factor,
particularly under hypoxic stress.
Effect of VEGF blockade on Bcl-2 and Bad expression.
Expression of the anti-apoptotic protein Bcl-2 and the pro-
apoptotic protein Bad was examined under normoxia and
hypoxia with and without VEGF blockade (VEGF neutralising
antibody). Hypoxia (2% O2) resulted in a significant increase
in Bcl-2 relative to normoxia in 4T1 and MDA-MB-231 cells
(4T1, 159±26.69%, Fig. 5A; MDA-MB-231, 248±60.00%,
Fig. 5B). Under normoxic conditions, anti-VEGF antibodies
had no significant effect on Bcl-2 expression in either cell line.
VEGF neutralising antibody significantly reduced hypoxia-
induced Bcl-2 in both cell lines (4T1, 107±14.74% vs
159±26.69%; MDA-MB-231, 171±33.84% vs 248±22.81%).
These data demonstrate that hypoxia-induced Bcl-2 expression
can be attenuated by VEGF blockade, particularly in MDA-
MB-231 tumour cells.
The effect of VEGF neutralisation on the expression of
the pro-apoptotic protein Bad was then examined. Under
normoxia, VEGF neutralising antibodies had no effect on Bad
protein expression in 4T1 and MDA-MB-231 cells (Fig. 5C
and D, respectively). Hypoxia decreased Bad expression
(4T1, 47±11.85%; MDA-MB-231, 35.67±9.20%) relative to
normoxia (normoxic controls were taken as 100%). VEGF
neutralising antibody increased Bad protein expression under
hypoxic conditions relative to hypoxic controls (lane 4) (4T1,
72±6.51% vs 47%; MDA-MB-231, 64.67±1.76% vs 35.67%),
although not to the level expressed in normoxic controls.
VEGF blockade had no effect on expression of the anti-
apoptotic protein, Bcl-2, or the pro-apoptotic protein, Bad, in
4T1 and MDA-MB-231 breast tumour cells under normoxia.
However, under hypoxic conditions, VEGF blockade affected
both sides of the apoptotic balance, decreasing Bcl-2 and
increasing Bad. These data suggest that different signalling
pathways may exist in 4T1 and MDA-MB-231 tumour cells,
by which VEGF blockade induces apoptosis under normoxia
and hypoxia.
Neutralising antibodies to VEGF abrogated hypoxia-induced
phosphorylation of Akt. Our data show that VEGF blockade
induces apoptosis and alters the Bcl-2/Bad ratio in breast
tumour cells. VEGF signalling mechanisms were examined in
4T1 and MDA-MB-231 cells. Akt phosphorylation in response
to recombinant VEGF and/or neutralising antibody to VEGF
under normoxia and hypoxia was therefore examined. Akt is
activated by a dual regulatory mechanism that requires both
translocation to the plasma membrane and phosphorylation at
Thr308 and Ser473 (24). Although Thr308 phosphorylation is
sufficient for Akt activation (25), maximal activation of Akt
also requires phosphorylation of Ser473 (26). We established
that maximum phosphorylation of Akt in response to VEGF
(100 ng/ml) occurred after 30 min (data not shown). This
induction of Akt phosphorylation by VEGF was inhibited by
wortmannin, indicating that VEGF-induced phosphorylation
of Akt occurred via PI3K.
4T1 tumour cells were cultured under normoxia and
hypoxia in the presence or absence of recombinant VEGF, the
PI3K inhibitor, wortmannin, in combination with recombinant
VEGF, neutralising antibody to VEGF or a combination of
recombinant VEGF and neutralising antibodies to VEGF,
BARR et al:  VEGF PREVENTS APOPTOSIS OF BREAST TUMOUR CELLS44
Figure 4. TUNEL staining of 4T1 (A) and MDA-MB-231 (B) tumour cells. Cells were incubated for 24 h under normoxia (21% O2) or hypoxia (2% O2) in the
presence or absence of VEGF neutralising antibodies (1 μg/ml). Apoptotic tumour cells (brown) were identified by TUNEL staining and morphology, as
indicated by arrows (original magnification x400).
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for 30 min in order to examine their effect on Akt phos-
phorylation. Blots were probed with a monoclonal antibody
which recognises Akt phosphorylation at Ser473. Relative to
controls, both recombinant VEGF or hypoxia increased Akt
phosphorylation in 4T1 cells (Fig. 6). This increase in Akt
phosphorylation under hypoxia may be due to hypoxia-induced
VEGF. Wortmannin blocked Akt phosphorylation to below
control levels under normoxia (Fig. 6A) and reduced the
phosphorylation induced by hypoxia (Fig. 6B). It may be
possible that the concentration of wortmannin used (500 nM)
may have been insufficient to completely block the increase
in Akt phosphorylation observed under hypoxia. VEGF
neutralising antibody inhibited Akt phosphorylation in 4T1
cells, an effect which was reversed by the addition of re-
combinant VEGF. Under hypoxia, VEGF neutralising antibody
also blocked Akt phosphorylation but recombinant VEGF
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Figure 5. Effect of VEGF neutralising antibodies on Bcl-2 and Bad protein
expression in 4T1 and MDA-MB-231 tumour cells under normoxia (21%
O2) or hypoxia (2% O2). Bcl-2 expression in 4T1 and MDA-MB-231 cells
(A and B, respectively) and Bad protein expression (C and D, respectively)
were examined under normoxia and hypoxia in the presence or absence of
VEGF neutralising antibodies (1 μg/ml) for 24 h. Blots were stripped and
re-probed for ß-actin to normalise for loading differences. Blots shown are
representative of three independent experiments. Densitometric analysis
of Bcl-2 (E and F) and Bad (G and H) protein expression in 4T1 and
MDA-MB-231 tumour cells relative to ß-actin expression. Protein expression
was normalised to ß-actin and expressed as a percentage of normoxic
controls which were taken as 100%. Data are expressed as the mean ± SEM.
Statistical analysis was performed by ANOVA with Scheffe post-hoc
correction (*p<0.05, hypoxia vs normoxia, $p<0.05, hypoxia + VEGF Ab vs
hypoxia, n=3). 
41-48  10/12/07  15:01  Page 45
only partially reversed this effect. These data suggest that
VEGF pro-survival signals in mammary adenocarcinoma cells
are mediated via the PI3K/Akt signalling pathway, promoting
phosphorylation of Akt. Moreover, these results suggest that
the induction of 4T1 tumour cell apoptosis by VEGF blockade
is at least, in part, mediated by preventing VEGF-induced Akt
phosphorylation, thereby blocking the anti-apoptotic effects
of VEGF under hypoxia. Although recombinant VEGF could
overcome the inhibition of Akt phosphorylation in response
to VEGF neutralisation under normoxia, this effect was only
partially seen by VEGF blockade under hypoxia.
Discussion
Tumours commonly outgrow their blood supply resulting in
hypoxic areas that stimulate the release of angiogenic cytokines
such as VEGF. This hypoxic stress also exerts a selective
pressure within tumours, supporting the expansion of cells
with reduced apoptotic potential (27). VEGF is one of the most
potent pro-angiogenic growth factors identified to date and
has been shown to protect endothelial cells from apoptosis
by inducing the anti-apoptotic protein, Bcl-2 (28), thereby
prolonging the survival of endothelial cells and sustaining
angiogenesis. VEGF protects haematopoietic cells and some
leukemic cell lines from chemotherapy-induced apoptosis, an
effect that involves the induction of Mcl-1, an anti-apoptotic
member of the Bcl-2 family (29). The role of VEGF as a
tumour cell survival factor via induction of Bcl-2 and inhibition
of apoptosis has been reported in a number of tumour types
such as neuroblastoma (30), leukaemia (17) and breast
carcinoma cells (18,19).
As 4T1 and MDA-MB-231 cells constitutively express
VEGF, blocking VEGF using neutralising antibodies to VEGF
was used to examine VEGF-mediated inhibition of tumour
cell apoptosis. In this study, anti-VEGF antibodies had a
direct effect on murine and human tumour cells, inducing
significant apoptosis under normoxia, but to a greater extent
under hypoxia. Under normoxic growth, tumour cells are
not subjected to stress and therefore, there is a minimum
requirement for VEGF. On the contrary, cells that are grown
under hypoxia, as in a solid tumour, are stressed. As a result,
there is an increase in VEGF expression, in which case tumour
cells may become dependent on VEGF for survival. VEGF
neutralising antibodies partially blocked hypoxia-induced
Bcl-2, suggesting a mechanism whereby VEGF-induced
expression of Bcl-2 may enhance the survival of mammary
adenocarcinoma cells and, more importantly, in hypoxia,
areas of solid tumours. These observations indicate that the
hypoxia-induced expression of Bcl-2 observed in 4T1 and
MDA-MB-231 breast tumour cells, was mediated through
VEGF. We investigated the mechanisms underlying VEGF-
mediated inhibition of tumour cell apoptosis. Under normoxia,
VEGF blockade had no effect on the expression of the anti-
apoptotic protein, Bcl-2, or the pro-apoptotic protein, Bad.
However, under hypoxic conditions, VEGF blockade affected
the balance between these anti- and pro-apoptotic Bcl-2
family members, suggesting that alterations in these proteins
underlie VEGF-mediated inhibition of tumour cell apoptosis,
particularly under low oxygen tensions. The decrease in
hypoxia-induced Bcl-2 and increase in Bad protein expression
in response to VEGF blockade suggest a role for these cell
death proteins as mediators of the pro-survival effect of VEGF
on hypoxic tumour cells. Other studies have demonstrated that
hypoxia protects breast tumour cells from apoptosis induced
by serum deprivation as a function of the integrin, α6ß1 (31)
and highlights the potential function for such integrins in
stimulating VEGF transcription and providing a survival
advantage for breast carcinoma cells under hypoxia. Such
observations are in agreement with our findings that breast
carcinoma cells depend on the autocrine effects of VEGF on
survival, particularly under low oxygen tensions and suggest
that signalling pathways by which VEGF blockade induces
apoptosis may be different under normoxic and hypoxic
growth conditions.
Phospho-Akt promotes cell survival by inhibiting apoptosis.
Phospho-Akt (Ser473) has been shown to specifically phos-
phorylate Bad, resulting in the inactivation of its pro-apoptotic
function (32). Our results show that, similar to its effects on
endothelial cells, VEGF phosphorylates Akt via the PI3K
signalling pathway. Decreased Akt phosphorylation in response
to VEGF blockade under normoxia and hypoxia is therefore
a possible mechanism whereby anti-VEGF strategies overcome
the autocrine survival effects of VEGF in breast tumour cells
and induce apoptosis.
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Figure 6. VEGF blockade inhibited the hypoxia-induced Akt phosphorylation
of breast tumor cells. 4T1 tumour cells were cultured under normoxia (21%
O2) (A) and hypoxia (2% O2) (B) for 30 min in the presence of 100 ng/ml
recombinant VEGF (rmVEGF), 500 nM wortmannin (Wm), 1 μg/ml VEGF
neutralising antibodies (VEGF Ab) or recombinant VEGF in combination with
VEGF neutralising antibodies (rmVEGF + VEGF Ab). Akt phosphorylation
was examined by Western blotting using an anti-phospho-Akt (p-Ser473)-
specific monoclonal antibody. Blots were stripped and reprobed for total Akt.
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NP1 was originally identified as a receptor for the collapsin/
semaphorin family that mediates neuronal cell guidance (33).
More recently, it has been identified as an isoform-specific
receptor for VEGF165 in endothelial cells and some tumour
cells (34). When co-expressed in cells expressing KDR/
VEGFR2 (kinase insert domain receptor), NP1 enhances
the binding of VEGF165 to KDR and VEGF165-mediated
chemotaxis. A role for VEGF in preventing tumour cell
apoptosis is further supported by reports demonstrating that
overexpression of soluble NP1, which prevents VEGF binding
to cell surface receptors in tumour cells, is associated with
tumour cell apoptosis (35). The importance of the NP1
receptor in maintaining survival of breast carcinoma cells and
haematopoietic stem cells has been described (36,37). 
A number of studies have examined the regulation of the
VEGF receptors, Flt-1/VEGFR-1 (fms-like tyrosine kinase),
KDR and NP1 by hypoxia. The hypoxic response in vivo was
demonstrated to differentially regulate the distribution of VEGF
and its receptors Flt-1 and KDR in specific cell types and
organs (38). Expression of Flt-1, but not KDR, was induced
by hypoxia in endothelial cells of the lung, heart, brain,
kidney and liver. In human astrocytoma cells, hypoxia was
shown to decrease NP1 expression (39). We show that both
VEGF and NP1 are upregulated by hypoxia. As NP1 has a
short intracellular domain and cannot transduce intracellular
signals alone, it has been suggested that complex formation
of NP1 with a co-receptor is necessary for signal transduction.
In neuronal cells, the effects of class III semaphorins are
mediated, at least in part, by NP1 and NP2, where NP1 is a
high-affinity receptor for Sema3A (40). Previous studies have
suggested that, while NP1 is necessary and sufficient for
growth cone binding of Sema3A, NP1 does not, by itself,
transmit a signal to the cytoplasmic domain of the growth
cone (41). Therefore, since the Neuropilins lack a functional
cytoplasmic signalling domain, class III semaphorins bind
to NP/Plexin receptor complexes. In doing so, the plexins
transduce the signal to downstream cytoplasmic molecules
(42). At present, it is unclear as to the mechanism of NP1
signalling in the absence of the classical VEGF tyrosine-
kinase receptors, Flt-1 and KDR, as the NP1 receptor lacks a
cytoplasmic signalling domain. We have previously shown
that NP1 plays an essential role in autocrine anti-apoptotic
signalling by VEGF in 4T1 and MDA-MB-231 tumour cells
which do not express the VEGF tyrosine kinase receptor,
KDR (23). Using a peptide corresponding to the NP1 binding
site on VEGF165, NP1 blockade induced tumour cell and
endothelial cell apoptosis. Accumulating data also suggest a
role for NP1 in VEGF-dependent survival in endothelial,
tumour and neuronal cells (18,34,43). Our findings demonstrate
that NP1 is upregulated under hypoxia, which increases VEGF.
Because survival during hypoxia depends on VEGF, it is
possible that NP1 enhances the VEGF-survival effect in these
cells, where hypoxia stimulates VEGF-dependent signalling
not only by upregulation of the VEGF ligand, but also by
functional upregulation of the NP1 receptor.
Evidence that VEGF is an autocrine survival factor for
tumour cells has important implications for the efficacy of anti-
cancer therapies. Decreased apoptotic potential or resistance
to apoptosis is well recognised in virtually all known human
malignancies and provides malignant cells with a selective
growth advantage, allowing proliferation even in the face of
radiation and chemotherapy. Moreover, both radiation and
chemotherapy induce VEGF which may inadvertently protect
some cells from apoptosis. Blocking autocrine anti-apoptotic
VEGF signalling may account, in part, for the synergistic
effect of anti-VEGF strategies in combination with ionising
radiation and chemotherapy, rendering tumour cells more
susceptible to apoptosis. 
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